US 7,601,837 B2
Quinoline derivatives and their use as 5-HT6 ligands
Mahmood Ahmed, Harlow (United Kingdom); Christopher Norbert Johnson, Harlow (United Kingdom); Gregor James MacDonald, Harlow (United Kingdom); Stephen Frederick Moss, Harlow (United Kingdom); Mervyn Thompson, Harlow (United Kingdom); and David R Witty, Harlow (United Kingdom)
Assigned to Glaxo Group Limited, Greenford, Middlesex (United Kingdom)
Filed on Sep. 05, 2008, as Appl. No. 12/205,079.
Application 12/205079 is a continuation of application No. 10/509078, granted, now 7,452,888, previously published as PCT/EP03/03197, filed on Mar. 25, 2003.
Claims priority of application No. 0207289.0 (GB), filed on Mar. 27, 2002; and application No. 0225678.2 (GB), filed on Nov. 04, 2002.
Prior Publication US 2009/0036682 A1, Feb. 05, 2009
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 215/40 (2006.01)
U.S. Cl. 544—363  [514/253.07] 3 Claims
 
1. A crystalline form of 3-phenylsulfonyl-8-piperazin-1-yl-quinoline, wherein said crystalline form provides an X-ray powder diffraction pattern substantially in accordance with FIG. 3.